ALK-Abello B (ALKb)

Currency in DKK
226.00
-0.60(-0.26%)
Closed·
ALKb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
223.60227.80
52 wk Range
130.70237.60
Key Statistics
Prev. Close
226.6
Open
226
Day's Range
223.6-227.8
52 wk Range
130.7-237.6
Volume
145.44K
Average Volume (3m)
151.72K
1-Year Change
41.1%
Book Value / Share
27.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALKb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
219.33
Downside
-2.95%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

ALK-Abello B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

ALK-Abello B Company Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that provide support, guidance, and relief, as well as smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. It has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX, a grass pollen allergy tablet; CEDARCURE, a tablet for the treatment of Japanese cedar pollen induced allergy; and MITICURE for the treatment of house dust mite-induced allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Employees
2764
Market
Denmark

Compare ALKb to Peers and Sector

Metrics to compare
ALKb
Peers
Sector
Relationship
P/E Ratio
45.5x12.2x−0.6x
PEG Ratio
1.09−0.440.00
Price/Book
8.1x3.9x2.6x
Price / LTM Sales
8.2x2.8x3.3x
Upside (Analyst Target)
1.5%20.0%42.7%
Fair Value Upside
Unlock15.0%4.7%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 219.33
(-2.95% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy185.00-18.14%153.00UpgradeJan 30, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
1.40 / 1.40
Revenue / Forecast
1.53B / 1.47B
EPS Revisions
Last 90 days

ALKb Income Statement

People Also Watch

42.60
HLUNb
-0.93%
96.00
STOGR
-0.72%
4.024
HRA
-0.15%
216.0
DEMANT
+1.22%
113.300
TLXGn
+0.89%

FAQ

What Is the ALK-Abello B (ALKb) Stock Price Today?

The ALK-Abello B stock price today is 226.00

What Stock Exchange Does ALK-Abello B Trade On?

ALK-Abello B is listed and trades on the Copenhagen Stock Exchange stock exchange.

What Is the Stock Symbol for ALK-Abello B?

The stock symbol for ALK-Abello B is "ALKb."

What Is the ALK-Abello B Market Cap?

As of today, ALK-Abello B market cap is 49.99B.

What Is ALK-Abello B's Earnings Per Share (TTM)?

The ALK-Abello B EPS (TTM) is 4.97.

When Is the Next ALK-Abello B Earnings Date?

ALK-Abello B will release its next earnings report on Feb 20, 2026.

From a Technical Analysis Perspective, Is ALKb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ALK-Abello B Stock Split?

ALK-Abello B has split 1 times.

How Many Employees Does ALK-Abello B Have?

ALK-Abello B has 2764 employees.

What is the current trading status of ALK-Abello B (ALKb)?

As of Jan 06, 2026, ALK-Abello B (ALKb) is trading at a price of 226.00, with a previous close of 226.60. The stock has fluctuated within a day range of 223.60 to 227.80, while its 52-week range spans from 130.70 to 237.60.

What Is ALK-Abello B (ALKb) Price Target According to Analysts?

The average 12-month price target for ALK-Abello B is DKK219.33333, with a high estimate of DKK243 and a low estimate of DKK185. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -2.95% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.